XTL Biopharmaceuticals (XTLB)
(Delayed Data from NSDQ)
$2.42 USD
+0.02 (0.92%)
Updated Apr 26, 2024 03:50 PM ET
Pre-Market: $2.65 +0.23 (9.41%) 9:26 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for XTL Biopharmaceuticals Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 6 | 6 | 7 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 4 | 6 | 6 | 7 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 4 | 7 | 7 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 0 | 0 | 0 | 0 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 0 | 1 | 0 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 14 | 14 | 13 | 13 |
Capital Surplus | NA | 146 | 146 | 148 | 148 |
Retained Earnings | NA | -156 | -155 | -155 | -154 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 4 | 5 | 6 | 7 |
Total Liabilities & Shareholder's Equity | NA | 4 | 7 | 7 | 7 |
Total Common Equity | 0 | 4 | 5 | 6 | 7 |
Shares Outstanding | 5.40 | 5.40 | 5.40 | 5.10 | 5.10 |
Book Value Per Share | 0.00 | 0.74 | 0.99 | 1.23 | 1.37 |
Fiscal Year End for XTL Biopharmaceuticals Ltd falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 2 | 2 | 3 |
Receivables | NA | NA | NA | NA | 0 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | NA | NA | NA | NA | 0 |
Other Current Assets | NA | NA | 0 | 0 | 0 |
Total Current Assets | NA | NA | 2 | 3 | 3 |
Net Property & Equipment | NA | NA | NA | NA | 0 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | NA | NA | NA | NA | 0 |
Intangibles | NA | NA | 0 | 0 | 0 |
Deposits & Other Assets | NA | NA | NA | NA | 0 |
Total Assets | NA | NA | 3 | 3 | 3 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | NA | NA | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | NA | NA | NA | 0 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 0 |
Income Taxes Payable | NA | NA | NA | NA | 0 |
Other Current Liabilities | NA | NA | NA | NA | 0 |
Total Current Liabilities | NA | NA | 0 | 0 | 0 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | NA | NA | NA | NA | 0 |
Convertible Debt | NA | NA | NA | NA | 0 |
Long-Term Debt | NA | NA | NA | NA | 0 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | NA | NA | NA | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | NA | NA | 0 | 0 | 0 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 0 |
Common Stock (Par) | NA | NA | 14 | 14 | 14 |
Capital Surplus | NA | NA | 146 | 146 | 146 |
Retained Earnings | NA | NA | -158 | -158 | -157 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | NA | NA | 3 | 3 | 3 |
Total Liabilities & Shareholder's Equity | NA | NA | 3 | 3 | 3 |
Total Common Equity | 0 | 0 | 100,002 | 100,002 | 3 |
Shares Outstanding | 5.40 | 5.40 | 5.40 | 5.40 | 5.40 |
Book Value Per Share | 0.00 | 0.00 | 18,518.80 | 18,518.84 | 0.57 |